Prochlorperazine Maleate
NDC Package 67296-1405-5

11-digit billing NDC: 67296140505

Package Information

This product is EXCLUDED from the official NDC directory because the listing data was inactivated by the FDA.

Prochlorperazine Maleate is tablets are indicated for the control of severe nausea and vomiting.Prochlorperazine maleate tablets are also indicated for the treatment of schizophrenia.Prochlorperazine is effective for the short-term treatment of generalized non-psychotic anxiety. Marketed by Redpharm Drug, Inc., this product is identified by NDC 67296-1405 and is authorized under FDA application ANDA040185.

Identification & Billing

NDC Package Code
67296-1405-5
Package Description
15 TABLET, FILM COATED in 1 BOTTLE
Product Code
11-Digit Billing Format
67296140505
RxNorm Crosswalk

Clinical Specifications

Proprietary Name
Prochlorperazine Maleate
Dosage Form
-
Usage Information
Prochlorperazine maleate tablets are indicated for the control of severe nausea and vomiting.Prochlorperazine maleate tablets are also indicated for the treatment of schizophrenia.Prochlorperazine is effective for the short-term treatment of generalized non-psychotic anxiety. However, prochlorperazine maleate tablets are not the first drug to be used in therapy for most patients with non-psychotic anxiety, because certain risks associated with its use are not shared by common alternative treatments (e.g., benzodiazepines).When used in the treatment of non-psychotic anxiety, prochlorperazine maleate tablets should not be administered at doses of more than 20 mg per day or for longer than 12 weeks, because the use of prochlorperazine maleate tablets at higher doses or for longer intervals may cause persistent tardive dyskinesia that may prove irreversible (see WARNINGS).The effectiveness of prochlorperazine as treatment for non-psychotic anxiety was established in 4-week clinical studies of outpatients with generalized anxiety disorder. This evidence does not predict that prochlorperazine maleate tablets will be useful in patients with other non-psychotic conditions in which anxiety, or signs that mimic anxiety, are found (e.g., physical illness, organic mental conditions, agitated depression, character pathologies, etc.).Prochlorperazine has not been shown effective in the management of behavioral complications in patients with mental retardation.

Regulatory & Marketing

Labeler Name
Redpharm Drug, Inc.
FDA Application #
ANDA040185
Marketing Category
ANDA - A product marketed under an approved Abbreviated New Drug Application.
Start Marketing Date
11-18-1996
Listing Expiration
12-31-2021
Exclude Flag
I
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 67296-1405-5 identifies a specific commercial package of 15 tablet, film coated in 1 bottle of Prochlorperazine Maleate, labeled by Redpharm Drug, Inc.. This is formulated for use and contains as the active substance.

Is this product currently listed with the FDA?

This product code is currently listed as inactive or excluded from the primary directory. It was introduced to the market by Redpharm Drug, Inc. on November 18, 1996. The current certification is valid through December 31, 2021.

How is this Redpharm Drug, Inc. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 67296140505. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-4-1)
67296-1405-5
11-Digit CMS (5-4-2)
67296-1405-05

Note: The zero is added to the Package segment to maintain the 5-4-2 structure.